Subash Jonnalagadda

  • 611 Citations
  • 15 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Research Expertise: 
Organic & Medicinal Chemistry | Organoboron Chemistry | Alternate Energy Materials

Medicinal Chemistry: We have been developing novel aza- and bora-heterocyclic compounds and betulin-based natural product derivatives as anti-cancer agents. In collaboration with Rowan School of Osteopathic Medicine, we have also identified few Withaferin-serotonin conjugates as potential therapeutic options for the treatment of Alzheimers’ Disease.

Value Added Chemicals from Biomass: Recent efforts in this area have included the development of new protocols for the effective conversion of biomass derived cellulosic materials into chemicals such as hydroxymethyl furfural and furan dicarboxylic acid for applications as bio-based polymers.

Honors and Awards:
Rowan University Wall of Fame Teaching Award, 2013, 2016
Eli Lilly International Graduate Scholar, 2000-2005, Purdue University

Member of:
American Chemical Society (

Education/Academic qualification

Doctor of Philosophy, doctorate

Bachelor of Science, Bachelor, Pondicherry University

Master of Science, Master, University of Hyderabad

Fingerprint Dive into the research topics where Subash Jonnalagadda is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

  • 611 Citations
  • 15 h-Index
  • 28 Article
  • 6 Chapter
  • 2 Review article
  • 1 Comment/debate

Nucleic acid delivery with α-tocopherol-polyethyleneimine-polyethylene glycol nanocarrier system

Nawshad Hossian, A. K. M., Jois, S. D., Jonnalagadda, S. C. & Mattheolabakis, G., 2020, In : International Journal of Nanomedicine. 15, p. 6689-6703 15 p.

Research output: Contribution to journalArticle

Open Access
  • Old drugs, new uses: Drug repurposing in hematological malignancies

    Kale, V. P., Habib, H., Chitren, R., Patel, M., Pramanik, K. C., Jonnalagadda, S. C., Challagundla, K. & Pandey, M. K., Jan 1 2020, (Accepted/In press) In : Seminars in Cancer Biology.

    Research output: Contribution to journalReview article

  • 1 Scopus citations

    Synthesis and biological evaluation of arylphosphonium-benzoxaborole conjugates as novel anticancer agents

    Jonnalagadda, S. K., Wielenberg, K., Ronayne, C. T., Jonnalagadda, S., Kiprof, P., Jonnalagadda, S. C. & Mereddy, V. R., Jul 15 2020, In : Bioorganic and Medicinal Chemistry Letters. 30, 14, 127259.

    Research output: Contribution to journalArticle

  • Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity

    Fultang, N., Illendula, A., Chen, B., Wu, C., Jonnalagadda, S., Baird, N., Klase, Z. & Peethambaran, B., May 2019, In : PloS one. 14, 5, e0217789.

    Research output: Contribution to journalArticle

    Open Access
  • 6 Scopus citations

    Benzoboroxoles: Synthesis and applications in medicinal chemistry

    Mereddy, G. R., Chakradhar, A., Rutkoski, R. M. & Jonnalagadda, S. C., Jun 15 2018, In : Journal of Organometallic Chemistry. 865, p. 12-22 11 p.

    Research output: Contribution to journalArticle

  • 9 Scopus citations